Rhythm Pharmaceuticals (RYTM) PT Lowered to $33 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Price: $93.07 --0%
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 23 | New: 0
Rating Summary:
19 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 2 | Down: 23 | New: 0
Join SI Premium – FREE
BofA Securities analyst Tazeen Ahmad lowered the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $33.00 (from $35.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pinterest Inc (PINS) PT Lowered to $23 at BofA Securities
- Cheniere Energy (LNG) PT Raised to $350 at BofA Securities
- Amazon.com (AMZN) PT Lowered to $317 at BofA Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
